Why Partner

The 8th RNAi-Based Therapeutics Summit brings together the scientists, innovators and business leaders driving RNAi progress. This field is rapidly advancing beyond liver-directed therapies and as such, developers face increasing challenges around delivery, manufacturing, translational predictability and commercialization.

Whether you offer oligonucleotide synthesis, characterization, sequencing, CDMO or CRO services,  this is your chance to position your organization alongside the teams driving RNAi innovations and evaluating new technologies, services, and strategic partnerships.

A growing repertoire of promising clinical data and high-profile funding and partnership opportunities expanding the RNAi space is creating a growing demand for partners capable of accelerating development and reducing risk. Through engagement with the RNAi community, we’ve identified these challenges they’re facing:

• Achieving targeted extrahepatic delivery across the CNS, muscle, adipose and kidney tissues
• Navigating CMC, manufacturing and regulatory complexities for next-generation RNAi modalities
• Accelerating clinical translation for neurological, metabolic and oncology-focused RNAi therapies

The 8th RNAi-Based Therapeutics Summit is a highly-focused, intimate event with dedicated networking sessions to allow you to connect and engage with the decision-makers in the RNAi community, creating relationships that can extend beyond the event itself.

Partner with us in 2027 for this unique opportunity to showcase your technologies, services and expertise directly to companies actively evaluating external partners and solutions.